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Liquid-Chromatographic Determination of lndole-3-acetic Acid and
5-Hydroxyindole-3-acetic Acid in Human Plasma
E. MartInez, F. Artigas, C. Su#{241}ol,J. M. Tusell, and E. Gelpi
We describe a “high-performance” reversed-phase liquid-
chromatographic method for determination of indole-3-acetic
acid (I) and 5-hydroxyindole-3-acetic acid (II) in human
plasma. I is eluted at 1.0 mL/min with a mixture of 1-
pentanesulfonic acid (pH 3.1), methanol, and water. It is
detected by fluorometry. A mixture of citric acid/sodium
phosphate solution (pH 4.8) and methanol, at 1.5 mL’min, is
used to elute II, which is detected with an electrochemical
cell. Platelet-poor plasma samples were pretreated with HCI,
perchloric acid, and trichloroacetic acid for protein precipita-
tion. Best results were obtained with the last (protein precipi-
tation is incomplete with HCI, while recoveries of I are
concentration dependent with perchloric acid). Analytical
recoveries were 58% (SD 3.1%, CV 5.3%, n = 12) and 79%
(SD 3.3%, CV 5.3%, n = 9) for I and II, respectively.
Concentrations of I and II in plasma ranged from 0.61 to 3.32
(mean 1.54, SD 0.59, n = 15) mol/L and from 33.0 to 102.6
(mean 51.8, SD 20.1, n = 16) nmol/L, respectively.
AddItIonal Keyphrases: reference value fluorometiy elec-
trochemical detection . neurological and psychiatric disorders
bio-amines
The metabolism of 5-hydroxytryptamine has been impli-
cated in the etiology of psychiatric disorders such as depres-
sive states (1) as well as in other neurological alterations
(for a review, see 2). Also, alterations of 5-hydroxytrypta-
mine metabolism have been described in the carcinoid
syndrome (3) as well in several types of cancer (4). 5-
Hydroxytryptamine, which is derived from tryptophan
through ring hydroxylation (tryptophan hydroxylase, EC
1.14.16.4)and subsequent decarboxylation of 5-hydroxy-
tryptophan (aromatic L-aminoacid decarboxylase, EC
4.1.1.28) is mainly metabolized by deamination (monoamine
oxidase, EC 1.41.3.4), yielding 5-hydroxyindole-3-acetic acid
(5HIAA).1 Measurements of the concentration of this catab-
olite in the cerebrospmal fluid have been used as an index of
serotonergic activity in the central nervous system (5) or,
measured in urine, as an index of total 5-hydroxytrypta-
mine activity (6).
The behaviorally-active trace amine, tryptamine, is pro-
duced in mammals through decarboxylation of tryptophan,
a common precursor of both amines. At present, several
lines of evidence suggest a possible neuromodulator activity
of tryptamine in the central nervous system (7-9). However,
to date, no clear implications of the metabolism of this
amine in psychiatric disorders have been proven, even
though several classic treatments of depressive states (tryp-
tophan loading, monoamine oxidase inhibitor administra-
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tion) have been shown to increase the concentration of
tryptamine in the brain dramatically (10). Also, because it
readily crosses the blood-brain barrier (11), peripheral
metabolism of this amine can influence its availability in
brain. Tryptamine is also deaminated by monoamine oxi-
dase, yielding indole-3-acetic acid (IAA). The ratio between
IAA and tryptamine, measured in urine, has been used as
an index of monoamine oxidase activity in humans (12).
Thus, the concentrations of either 5HIAA and IAA, or
both, can be taken as an index of the functional activity of
the indoleaminergic pathways of tryptophan, and conse-
quently both acids have been measured in cerebrospinal
fluid (5, 13) and urine (6, 14). However, to our knowledge,
there are no published values for either of these compounds
in normal human plasma.
As a part of a more-complex study concerning the concen-
trations of tryptophan, tryptamine, serotonin, IAA, and
5HIAA in platelets and platelet-poor-plasma (PPP) samples
from healthy individuals and depressive patients, we pre-
sent here a liquid-chromatographic assay of 5HIA.A and
IAA in plasma samples from healthy volunteers.
Both compounds were chromatographed on a reversed-
phase column. The low concentration of 5HIAA in plasma
samples required use of an electrochemical detector. IAA
was monitored fluorometrically, capitalizing on the relative-
ly strong natural fluorescence of indolic compounds.
Several gas-chromatographic/mass-spectrometric tech-
niques are available for use in analysis for both compounds
in cerebrospinal fluid and brain tissue (5, 13, 15-17) but we
consider “high-performance” liquid chromatography
(HPLC) coupled to specific detectors such as the electro-
chemical or fluorometric detectors to be the analytical
technique of choice because there is less sample handling,
easier automation, and faster analysis.
Materials and Methods
Reagents
All chemicals were of analytical grade. Methanol used as
chromatographic eluent was “HPLC” grade.
Standards
Stock 1.0 g/L solutions of 5HIAA and IAA (Sigma Chemi-
cal Co., St. Louis, MO 63178) were prepared weekly in
isotonic saline and stored at 4#{176}C.Working standards were
freshly prepared by diluting stock solutions.
Qualitative stock solutions of tryptophan, tryptaniine, 5-
hydroxytryptamine, 4-hydroxy-3-methoxymandelic acid, do-
pamine, 3,4-dihydroxyphenylacetic acid, 4-hydroxy-3 meth-
oxy phenylethyleneglycol, 4-hydroxy-3-methoxy phenylace-
tic acid, indole-3-pyruvic acid, and indole-3-propionic acid
were prepared, with the chromatographic eluent system as
the solvent.
Apparatus
We used a M6000 solvent-delivery system with an auto-
matic sample injector (WISP 710B; Waters Associates Inc.,
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Milford, MA 01757), a Model 650-lOS fluorescence detector
(Perkin-Elmer Corp., Norwalk, CT 06856) or a Model LC-4A
amperometric detector (Bioanalytical Systems Inc., West
Lafayette, IN 47906), and a Model 56 (Perkin-Elmer) re-
corder.
The chromatographic column was 30 cm long, 3.9 mm i.d.,
ifiled with jzBondapack C18 reversed phase (Waters Assoc.).
A guard column (tBondapack C18, also from Waters Assoc.)
was attached btween the injector and the chromatographic
column.
For chromatographic analysis with fluorometric detection
we used a mobile phase consisting of an equivolume mixture
of 1-pentanesulfomc acid (PlC B-5, Waters Assoc.) 5 mmoli
L, pH 3.1, and methanol/water (7/3 by vol), at a flow rate of
1.0 mL/min. Excitation and emission wavelengths were set
at 280 nm and 340 nm, respectively.
When the electrochemical detector was used, the mobile
phase consisted of a 94/6 (by vol) mixture (pH 4.8) of citric
acid 30 mmolJL), disodium hydrogen phosphate (60 mmol/L)
and methanol, at a flow rate of 1.5 mL/min. The potential of
the glassy carbon electrode was set to 0.55 V vs the Ag/AgCl
reference electrode.
Plasma Samples
Blood was sampled from ostensibly healthy adult volun-
teers who had fasted overnight. Samples were drawn by
venipuncture at 0900 hours into polypropylene tubes con-
taining EDTA in saline (5.0 g/L; one vol per three vol of
blood). The contents of the tubes were gently mixed by
several inversions. PPP samples were obtained by centrifug-
ing the whole blood (1000 x g, 10 mm, 4 #{176}C).The supernates
were carefuly removed and stored at -40 #{176}Cuntil analyzed.
For methodological studies we used a single specimen of
plasma, corresponding to 100 mL of blood from one donor.
Observed values were derived by use of 3-mL specimens
from each of 16 different healthy individuals.
Procedure
To 0.2 mL of PPP in a polypropylene tube, add 40 L of a
20 g/L ascorbic acid solution and either 25 L of cold
concentrated perchloric acid (PCA) or 300 L of a 50 g/L
solution of trichioroacetic acid (TCA). Shake the mixture
vigorously, allow it to stand for 5 mm, then centrifuge (2000
x g, 15 mm). When PCA is used, adjust the pH of the clear
supernate to 1.5-2 with a 10 inol/L solution of NaOH. Do all
of the above at 4 #{176}C.
Inject aliquots of the supernate directly into the liquid
chromatograph. Run the chromatographic analyses at room
temperature.
Quantification
PPP samples were supplemented with the appropriate
amounts of IAA or 5HLAA (see results) and subjected to the
procedure described above. The endogenous 5HIAA or IAA
in plasma was calculated in each sample by comparing peak
heights of the corresponding “endogenous” and “supple-
mented” aliquots.
Results
Both acid metabolites, IAA and 5HIAA, were chromato-
graphed on the same reversed-phase column, as described in
the previous section. However, the choice of the most
suitable detector system was based in each case on the
sensitivity of response needed to work within the physiologi-
cal working range. For instance, a few picograms of 5HIAA
can readily be detected by an electrochemical cell operated
at 0.5-0.7 V (18, 19). In contrast, detection of IAA would
require a relatively higher electrochenucal detector elec-
trode potential, which in turn would generate a high inter-
fering background signal, because of the oxidation of many
other components of the samples, thus masking the response
of endogenous IAA. Consequently, this strongly fluorescent
acid is best monitored fluorometrically. Figure 1 (A and B)
shows the chromatographic profiles of both acids in plasma.
Detection limits for both compounds have been reported
elsewhere (19,20). We recently reported a liquid-chromato-
graphic procedure for determining 5HIAA, with electro-
chemical detection, in brain tissue (19); the procedure for
IAA is a modification of another method, also recently
reported (20). The advantage of the latter is that because it
is an isocratic elution procedure, as for the 5HIAA determi-
nation, it facilitates the use of an automatic injector, which
is convenient in routine work.
The excellent performance of these chromatographic pro-
cedures, not only in terms of sensitivity but also of specific-
ity-both peaks are free from coeluting interferences (Table
1)-and reproducibility of retention time (Table 1), make
them particularly suitable for the kind of determinations we
report here. Furthermore, the conspicuous absence of pub-
lished reference or observed values is the natural conse-
quence of the lack hitherto of simple, reliable analytical
methods for assay of these compounds. Thus, after we
developed an adequate HPLC procedure with standards, we
Fig. 1. HPLC profiles of fAA and 5HIAA from plasma samples
A, fluorometric response with the 1-pantanesulfonic acid/methanol eluentsystem.
B, amperometric response with the citrate/phospate/rnethanol eluent system
Table 1. Relative Retention Volumes of Some
Indole- and Catechol-ReIated Compounds
Compound V,,JV,,,. V’V,
4-Hydroxy-3-methoxymandelic acid
Dopamine
3,4-Dihydroxyphenylacetic acid
4-Hydroxy-3-methoxyphenylethyleneg$ycol
5-Hydroxytryptamine
5-Hydroxyindole-3-acetic acid
4-Hydroxy-3-methoxyphenylacetic acid
lndole-3-pyruvic acid
Tryptophan
Tryptamine
lndole-3-acetic acid
lndole-3-propionic acid
a Relative retention volumes in the citrate/phosphate/methanol system.
Retention volume of 5HIAA: 14.99 (SD 0.24) mL (n =32).
b Relativeretentionvolumes in the 1-pentanesulfonic acid methanol system.
Retentionvolume of IAA: 11.87 (SD 0.28) mL (n =30).
Table 2. Analytical Recoveries and Quantitation of
IAA in Platelet-Poor Plasma Treated with
Trichioroacetic acid
IAA, pmol/L Recovery, %
Concn added Endogenous concn
0.38 1.46 62.6
0.75 1.63 56.0
1.51 1.60 56.4
3.77
mean
1.58
1.57 (SD 0.07)a
57.0
mean 58.0 (SD 3.1)
next assessed the pretreatment steps necessary to render
blood samples suitable for direct chromatographic assay,
optimizing recoveries and sample stabilities.
For the sake of simplicity and speed, our first attempts
involved addition of 1 moLIL HC1 to the plasma samples, to
adjust their pH to 2.0 before injecting them into the liquid
chromatograph, a convenient way to stabilize indoles (6,21).
However, HC1 was unsatisfactory, especially for a mobile
phase containing 50% methanol; column filters become
clogged with protein, column pressure increases, and resolu-
tion becomes poor. In fact, after no more than 10 injections,
chromatographic performance was appreciably degraded.
The HC1 procedure would contribute to preventing losses of
IAA through its possible occlusion by the precipitating
proteins, thus facilitating the quantitative assay by external
calibration, but it would not be useful in practice for the
above reasons. The mean value obtained in this way for five
determinations of the plasma sample used for calibration of
the method was 1.25 (SD 0.04) mol/L.
To obviate this problem, we removed plasma proteins by
precipitation with either PCA or TCA. The advantages of
either one of these deproteinizing agents in the assay of IAA
in human plasma were evaluated as follows. Twelve 2O0-tL
samples of donor’s PPP were each supplemented . with in-
creasing amounts of authentic IAA (final concentration of
added IA.A: 0.38 to 3.77 MmoIfL), thus obtaining four groups
of three samples each. These were assayed by HPLC after
protein precipitation with either PCA or TCA. For plasma
samples treated with PCA, the CV of each of the replicate
data points was 3.2%. The points lay along a straight line
defined by the intercept and slope included in Figure 2A.
The corresponding correlation coefficient was r2 = .9990 and
the experimentally measured endogenous IAA peak height
was 66.6 units, in agreement with the calculated value of
65.4 (see intercepts in Figure 2A). Figure 2A also shows the
regression line corresponding to IAA standard solutions
treated as plasma samples, and run in duplicate. The
calculated average recovery for the four different concentra-
tions of IAA (n = 12) was 25.8 (SD 5.7), the CV 22%.
However, recovery was found to depend on the concentra-
tion of IAA. It increased in parallel with the amount added,
(A)
a This concentration of IAA in PPP would be equivalent to a concentration of
2.09 mol/L in human plasma.
which effectively invalidates the method for practical pur-
poses.
On the other hand, plasma samples treated with TCA
gave a straight line, the CV being 2.3% for each of the
triplicate measurements. In this case, the regression equa-
tion is as shown in Figure 2B. The measured LAA peak
height in the chromatogram of the unsupplemented sample
was 81.3. Similarly, standard solutions of increasing concen-
trations of IAA, each treated with TCA as with actual
plasma samples, gave a straight line (Figure 2B) intersect-
ing the x-axis at 65 fmol of IAA, equivalent to 11.4 pg. The
mean recovery improved in this case to 58% with SD = 3.1
and CV = 5.3% for n = 12 and, in contrast to the variation
observed when PCA was used, the recovery values for
different IAA concentrations in plasma are similar within
the working range 0.38-3.77 j.tmol/L (Table 2).
Our results nevertheless prove that there are no degrada-
tive losses with either TCA or PCA, as shown by the
regression data corresponding to the standard solutions.
Furthermore, washing the PCA or TCA protein precipitate
does not increase recoveries by more than 15% at most,
whereas the additional dilution decreases the concentration
of the acids in the samples, thus diminishing sensitivity.
5HIAA (Figure 1B) was assayed in the same way, with
recoveries in this case of 78.8% (SD 3.3% and CV 4.2%).
Figure 3 shows the calibration plot for the determination of
endogenous values of this acid in human plasma treated
with TCA.
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50(19.2)
100
IAA n,YcI/L
Fig. 2. Response of IAA standards (0) and IAA-supplemented PPP (#{149})
after deproteinization treatment with (A) PCA and (B) TCA
A. The adjustedstraight line (y = a + bx) parameters for standards and PPP
were respectively a 7.104, b = 0.209, r2 = 0.9999, and a = 65.440, b = 0.069,
r2 = 0.9990. B. The corresponding parametersin TCA treatmentwere a =
-0.188, b 0.2208, r2 = 0.9993, and a = 81.494,b = 0.125, r2 = 0.9997.
Abcissa: concentration of AS,in the standardsand the concentration of exoge-
nous IAA addedto thePPP.Ordinate: the fluorometricresponse,in millimeterson
the recorder paper, corresponding to 50 L of injected sample. The figures shown
in parentheses correspondto theexperimentalvalueobtained for unsupplement-
ed PPP.
20 60
5HIAA nmol/L
Fig. 3. Response of 5HIAA standards (0) and 5HIAA-supplemented
PPP (#{149})after treatment with TCA
The acusted straight-lineparametersfor standards and PPPwere respectively a
= 1.260, b = 0.6537, r2 = 0.9997, and a = 20.513, b = 0.519, r2 = 0.9996.
Abcissa: the concentration of 5HIAA for the standards and the concentrationof
the exogenous 5HIAA addedto the PPP. Ordinate:the amperometric response,
in millimeters on the recorder paper, corresponding to 80 >L of injected samples.
The figure shown in parentheses corresponds to the experimental value obtained
for unsupplemented PPP
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n = 15(13 men, 2 women)
X = 1.54 moI/L
SD = 0.59 jzmol/L
Range 0.61-3.32 mol/L
Mean donor age 29 yr (SO 4.9; range 24-39).
n = 16 (14 men, 2 women)
X = 51.8 nmol/L
SD = 20.1 nmol/L
Range 33.0-1 02.6 nmol/L
CLINICAL CHEMISTRY, Vol. 29, No. 7, 1983 1357
Table 3. Mean Values for IAA and 5HIAA in
Human Plasma
IAA 5HIAA
The values observed for both acids are given in Table 3.
Interferences due to other related compounds also present in
plasma samples are ruled out by their significantly different
retention volumes (Table 1). Furthermore, the reproducibili-
ty of the retention data is excellent, as shown also in this
table for both acids, contributing further to the reliability of
the method.
A significant correlation (p < .05, n = 16) was found
between body weight and the concentration of 5HIAA in
plasma.
The observed values for both acids differ by a factor of 30,
IAA being greater than 5HIAA. This is interesting, because
IAA is the principal metabolite of tryptamine, and no clear
physiological or pathological roles have yet been found for it.
Work is in progress to determine the significance of this
relatively high IAA concentration in human plasma for
healthy volunteers.
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